UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: November 2025 (Report No. 5)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name intoEnglish)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annualreports under cover of Form 20-F or Form 40-F:

☒ Form 20-F            ☐ Form 40-F

CONTENTS

On November 19, 2025, IceCureMedical Ltd. (the “Company”) issued a press release titled “IceCure Reports Financial & Operational Results forthe Nine Months Ended September 30, 2025,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issueron Form 6-K. 

The press release attachedherewith as Exhibit 99.1 (excluding the third, fourth, and fifth paragraphs thereof) is incorporated by reference into the Company’sRegistration Statements on Form F-3 (Registration Nos. 333-258660,333-267272 and 333-290046)and Form S-8 (Registration Nos. 333-270982,333-264578, 333-262620and 333-281587), filed withthe Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-Kis submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirementsof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereuntoduly authorized.

3

Exhibit 99.1

IceCure Reports Financial & OperationalResults for the Nine Months Ended September 30, 2025

Momentum building in the U.S. and rising interestglobally following landmark FDA marketing
authorization for local cryoablation treatment of low-risk breast cancer

Demand for ProSense® systems expected toaccelerate in 2026

Total U.S. population of approximately 200,000patients, includes women aged 70+, those
not suitable for surgery and benign breast tumors

Conference call to be held today, November 19,2025 at 10:00 am Eastern Time

CAESAREA, Israel, November 19, 2025 –IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer ofminimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financialresults as of and for the nine months ended September 30, 2025.

In October 2025, the U.S. Food and Drug Administration(“FDA”) granted marketing authorization to IceCure’s De Novo application for the ProSense® cryoablation system for the localtreatment of breast cancer in patients ≥70 years of age with biologically low-risk tumors ≤1.5 cm in size and treated with adjuvantendocrine therapy.

“This was a landmark quarter forIceCure and the patients we aim to serve,” said Eyal Shamir, Chief Executive Officer of IceCure Medical. “TheFDA’s marketing authorization for ProSense® in low-risk breast cancer in women aged 70 and over marks a historic milestoneand validates years of rigorous clinical research, positioning IceCure at the forefront of minimally invasive breast cancer care. Inaddition to the 46,000 patients that are 70+, we believe there are an additional 88,000 patients not suitable for or willing to gothrough surgery and approximately 63,000 patients with benign breast tumors who can also benefit from cryoablation.”

“The immediate response to the FDA’sdecision has been overwhelming and we are getting interest in the U.S. and globally from new potential users including breast surgeons,interventional and breast radiologists who are asking for demonstrations and installations,” added Mr. Shamir. “Over the pastfew months, we’ve seen an uptick in probe sales to our installed base of existing ProSense® users in the U.S. and internationally.Further expanding ProSense®’s availability, we recently received regulatory approval in Switzerland for indications includingbreast cancer.”

“Our U.S. sales team is hard at work. Weexpect ProSense® installations and procedure volume to increase and are very optimistic about our commercial traction,” Shamirconcluded.

Upcoming Catalysts

Third Quarter 2025 and Recent Operational andClinical Highlights

Regulatory Approval in Switzerland– ProSense® and its cryoprobes are now cleared for commercial sales in Switzerland for indications including the treatment ofmalignant or benign tissue of the breast, lung, liver, kidney, and musculoskeletal (bone), including palliative interventions.

Lung Cancer

Endometriosis

Breast Cancer

Financial Results for the Nine Months EndedSeptember 30, 2025

Revenue for the nine months ended September 30,2025, was $2,100,000 compared to $2,416,000 for the nine months ended September 30, 2024, which included the recognition of $100,000 froma distribution agreement and other services in Japan. With the FDA’s marketing clearance for ProSense® in low-risk breast cancergranted in October of 2025, the Company expects continued fluctuations in quarterly revenues as commercial activities ramp up in the U.S.and globally. The $316,000 decline in sales was due to a decrease in sales in Japan, other territories in Asia, and North America, andwas partially offset by an increase in sales in Latin America.

Gross profit for the nine months ended September30, 2025, was $626,000, compared to $1,034,000 for the nine months ended September 30, 2024. Gross margin was 30% in the nine months endedSeptember 30, 2025, compared to 43% in the nine months ended September 30, 2024. Non-GAAP gross profit for the nine months endedSeptember 30, 2025 was $626,000 compared to $934,000 for the nine months ended September 30, 2024. Non-GAAP gross margin for the ninemonths ended September 30, 2025 was 30% compared to 40% for the nine months ended September 30, 2024. The changes in non-GAAP gross profitand non-GAAP gross margin, which exclude revenue from the exclusive distribution agreements and other services in Japan, was mostly attributableto the decrease of 9% in revenue from sales of ProSense® systems and disposables probes. Non-GAAP gross profit and non-GAAP grossmargin are financial measures that may be defined as “non-GAAP financial measures” by the U.S. Securities and Exchange Commission(“SEC”). For a reconciliation of these non-GAAP financial measures to the nearest comparable GAAP measure, see Appendix Ato this press release.

Research and development expenses for the ninemonths ended September 30, 2025 were $5,137,000, compared to $5,401,000 in the nine months ended September 30, 2024, primarily reflectinga reduction in service providers and consultants and clinical trials costs as the Company concluded its ICE3 study in 2024.

Sales and marketing expenses for the nine monthsended September 30, 2025 were $3,061,000, compared to $4,041,000 for the nine months ended September 30, 2024, primarily reflecting areduction in service providers and consultants. General and administrative expenses for the nine months ended September 30, 2025 were$3,306,000, compared to $2,763,000 nine months ended September 30, 2024, reflecting an increase primarily in service providers, consultantsand share based compensation.

Total operating expenses for the nine months endedSeptember 30, 2025 declined to $11,504,000 from $12,205,000 for the nine months ended September 30, 2024. The decrease in operating expenseswas attributable to reductions in research and development, and sales and marketing expenses, and partially offset by increases in generaland administrative expenses.

Net loss for the nine months ended September 30,2025, was $10,811,000, or $0.18 per share, relatively unchanged compared to a net loss of $10,839,000, or $0.22 per share, for the sameperiod last year.

As of September 30, 2025, the Company had cash,cash equivalents, including short-term deposits, of approximately $10.0 million, compared to $7.6 million as of December31, 2024. In July 2025, the Company successfully completed a rights offering, which was approximately two times oversubscribed, raising$10 million in gross proceeds to support commercialization of ProSense® and of the next-generation XSense™ system.

During the first ten months of 2025, the Companyraised $5.87 million in net proceeds from the sale of 5,425,806 ordinary shares under its at-the-market offering facility bringing itscash balance as of October 31, 2025 to $11.8 million.

Use of Non-U.S. GAAP Measures

In addition to disclosing financial results preparedin accordance with accounting principles generally accepted in the U.S. (U.S. GAAP), this press release contains certain financial measureswhich may be defined as “non-GAAP financial measures” by the SEC. The Company defines non-GAAP gross profit as gross profitless revenue from exclusive distribution agreements and other services. The Company has provided non-GAAP gross profit in this press releasebecause it is a key measure used by management and the board of directors as an indication of our gross profit from sales of our systemsand disposables and management believes that it is useful to investors’ understanding and assessment of the Company’s grossprofit without the impact of revenue recorded from the Company’s exclusive distribution agreements and other services. The Companyhas provided a reconciliation below of non-GAAP gross profit and non-GAAP gross margin to the most directly comparable financial measurecalculated and presented in accordance with U.S. GAAP. The non-GAAP financial measures disclosed by the Company should not be consideredin isolation or as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP and the financial resultscalculated in accordance with U.S. GAAP and reconciliations to those financial results should be carefully evaluated.

Conference call & webcast info:

Wednesday, November 19, 2025, at 10:00 am EST

US: 1-888-407-2553

Israel/International: +972-3-918-0696

A live webcast will be available at: https://www.veidan-conferenceing.com/icecure

A recording of the webcast will be available at:ir.icecure-medical.com/

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and marketsadvanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with theprimary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgicaltumor removal that is easily performed in a relatively short procedure. The Company’s flagship ProSense® system is marketed and soldworldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

Forward Looking Statement

This press release containsforward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Actof 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,”“believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identifyforward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses:the potential and expected benefits of the FDA’s marking authorization for ProSense®; anticipated U.S. and global commercialtraction; the planned rollout of ProSense® to clinical and commercial sites pending FDA review and agreement with post-market studyplans; potential reimbursement coverage and code updates; the timing and outcome of Terumo Corporation’s planned regulatory submissionin Japan; the expected design, timing, and impact of the post-market study; the Company’s expectations regarding procedure volume,installations, and sales momentum; and future regulatory, clinical, and commercial developments for ProSense® and XSense™. Importantfactors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-lookingstatements include, among others: the Company’s planned level of revenues and capital expenditures; the Company’s available cash and itsability to obtain additional funding; the Company’s ability to market and sell its products; legal and regulatory developments in theUnited States and other countries; the Company’s ability to maintain its relationships with suppliers, distributors and other partners;the Company’s ability to maintain or protect the validity of its patents and other intellectual property; the Company’s ability to exposeand educate medical professionals about its products; political, economic and military instability in the Middle East, specificallyin Israel; as well as those factors set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the yearended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC whichare available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions orchanges after the date of this release, except as required by law.

IR Contact:

Email: investors@icecure-medical.com

Michael Polyviou

Phone: 732-232-6914

ICECURE MEDICAL LTD.

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIALPOSITION

ICECURE MEDICAL LTD.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)

ICECURE MEDICAL LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)

APPENDIX A

NON-GAAP RECONCILIATIONS (Unaudited)

9